eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, announced the appointment of Jay Barth, M.D., to the company’s executive management team as Chief Medical Officer (CMO). Dr. Barth joins eGenesis with over 25 years of industry experience in clinical development and medical affairs, most recently having served as CMO of Ascidian Therapeutics.
“Dr. Barth brings a wealth of expertise to our world-class team and will play a pivotal role in executing on our upcoming clinical objectives. His experience advancing transformative, novel therapies will be invaluable to our unique and novel scientific approach,” said Michael Curtis, Ph.D., Chief Executive Officer, eGenesis. “We look forward to Dr. Barth’s contributions as we pursue our mission to develop safe and effective human-compatible organs that have the potential to revolutionize the treatment of organ failure.”
Also Read: Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow
“I am excited to join eGenesis at such a pivotal time for the Company, with several key milestones ahead in the Company’s breakthrough approach to organ transplantation,” said Dr. Barth. “I look forward to building the company’s clinical capabilities, alongside a dedicated team, to advance these programs and address a large unmet need in transplantation.”
Dr. Barth earned his B.A. from Columbia University and M.D. from the University of Pennsylvania School of Medicine. He is a member of the American Society of Human Genetics and American Society of Gene & Cell Therapy. Dr. Barth has featured authorship in numerous publications in the fields of medicine and clinical research.
SOURCE: Businesswire